| Companies sponsors |
Gilead Sciences (seladelpar) |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| Patient carer groups |
Gene People |
| Professional groups |
British Association for the Study of the Liver |
| |
British Hepatology Pharmacy Group |
| |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
Ipsen (elafibranor) (confidentiality agreement signed, participating) |
| |
ADVANZ Pharma (ursodeoxycholic acid, obeticholic acid) (confidentiality agreement not signed, not participating) |
| |
Dr. Falk Pharma UK (ursodeoxycholic acid) (confidentiality agreement not signed, not participating) |
| |
Galen (ursodeoxycholic acid) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals Europe (ursodeoxycholic acid) (confidentiality agreement not signed, not participating) |
| |
Strides Pharma UK (ursodeoxycholic acid) (confidentiality agreement not signed, not participating) |
| |
Wockhardt UK (ursodeoxycholic acid) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Scottish Society of Gastroenterology |
| |
Welsh Government |
| Relevant research groups |
None |